摘要
目的 研究卵巢癌肿瘤组织中白细胞介素-6(IL-6)和IL-6受体(IL-6R)的表达水平,及其与卵巢癌患者预后的关系.方法 选取潍坊医学院附属寿光市人民医院2006—2011年收治的94例卵巢癌患者的瘤组织样本为研究对象,通过免疫组化法考察瘤组织中IL-6和IL-6R的表达水平,采用Kaplan-Meier法分析患者生存数据,并采用Cox比例风险回归模型进行多变量分析.结果 94例患者中,39例(41.5%)表现出IL-6高表达,32例(34.0%)表现出IL-6R高表达.IL-6低表达及高表达卵巢癌患者的无进展生存期和总生存期比较差异未见统计学意义(P>0.05).IL-6R高表达卵巢癌患者的无进展生存期低于IL-6R低表达卵巢癌患者(P<0.05).Cox比例风险回归模型分析结果显示,IL-6R高表达(HR:2.388;95%CI:1.171~4.895;P=0.017)、首次术后残留肿瘤>1 cm(HR:2.262;95%CI:1.301~5.513;P=0.007)、FIGO分期为Ⅲ/Ⅳ期(HR:12.92;95%CI:4.080~57.172;P<0.001)是影响卵巢癌患者无进展生存期的独立风险因素.结论 IL-6R是影响卵巢癌患者无进展生存期的独立风险因素,可用于巢癌患者预后的判断.
Objective To study the expression of interleukin-6(IL-6)and IL-6 receptor(IL-6R)in ovarian cancer tissues and its relationship with prognosis of ovarian cancer patients.Methods The tumor tissue samples of 94 patients admitted to People's Hospital of Shouguang Affiliated to Weifang Medical College from 2006 to 2011 were selected as the research objects.The expression levels of IL-6 and IL-6R in tumor tissues were detected by immunohistochemistry.The survival data of patients were analyzed by Kaplan-Meier method.The Cox proportional hazard regression model was used for multivariate analysis.Results Of the 94 patients,39 cases(41.5%)showed high expression of IL-6,and 32 cases(34.0%)showed high expression of IL-6R.There was no significant difference in progression-free survival and overall survival between patients with low expression of IL-6 and patients with high expression of IL-6(P>0.05).The progression-free survival of patients with high expression of IL-6R was significantly lower than that of patients with low expression of IL-6R(P<0.05).Cox proportional hazard regression analysis showed that high expression of IL-6R(HR:2.388;95%CI:1.171-4.895;P=0.017),residual tumor after primary surgical>1 cm(HR:2.262;95%CI:1.301-5.513;P=0.007),and FIGO stageⅢ/Ⅳ(HR:12.92;95%CI:4.080-57.172;P<0.001)were independent risk factors of progression-free survival in patients with ovarian cancer.Conclusions IL-6R is an independent risk factor for progression-free survival of ovarian cancer patients and can be used for prognosis prediction in ovarian cancer patients.
作者
刘玉莹
谭志军
李昌生
Liu Yuying;Tan Zhijun;Li Changsheng(Department of Obstetrics and Gynecology,People’s Hospital of Shouguang Affiliated to Weifang Medical College,Shouguang 262700,China)
出处
《中国实用医刊》
2019年第19期27-31,共5页
Chinese Journal of Practical Medicine
